AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), analog, substituted form, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof non-inhibitory of platelets, wherein said NSAID is intrathecally delivered by intrathecal catheter.

Claims 2-3 (Canceled)

- 4. (Original) A method according to claim 1, wherein the non-steroidal antiinflammatory drug comprises choline magnesium trisalicylate.
- 5. (Original) A method according to claim 1, wherein the non-steroidal antiinflammatory drug comprises sodium salicylate.
- 6. (Original) A method according to claim 1, wherein the non-steroidal antiinflammatory drug comprises salicylamide.
- 7. (Original) A method according to claim 1, wherein the non-steroidal antiinflammatory drug comprises a deacetylated aspirin.

Claims 8-28 (Canceled)

- 29. (Currently Amended) A method for treating neuronal injury said method comprising intrathecally administering by intrathecal catheter to a subject having neuronal injury a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), analog, substituted form, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof that is non-inhibitory of platelets.
- 30. (Original) A method according to claim 29, wherein the NSAID is intraventricularly delivered.
- 31. (Original) A method according to claim 29, wherein the non-steroidal antiinflammatory drug comprises choline magnesium trisalicylate.
- 32. (Original) A method according to claim 29, wherein the non-steroidal antiinflammatory drug comprises sodium salicylate.
- 33. (Original) A method according to claim 29, wherein the non-steroidal antiinflammatory drug comprises salicylamide.
- 34. (Original) A method according to claim 29, wherein the non-steroidal antiinflammatory drug comprises a deacetylated aspirin.

Response to Office Action of February 18, 2005

- 35. (Previously Presented) A method according to claim 29, wherein the neuronal injury is caused by Lupus, inflammatory neuropathy, infection, transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.
- 36. (Currently Amended) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), analog, substituted form, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof non-inhibitory of platelets, wherein said NSAID is intraventricularly delivered by intraventricular catheter.
- 37. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.
- 38. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.
- 39. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.
- 40. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

Serial No. 10/049,327

Response to Office Action of February 18, 2005

41. (Currently Amended) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of choline magnesium trisalicylate, analog, substituted form, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.